Presentations to include data from IV-administered programs in genetic epilepsy due to STXBP1 mutations and Parkinson’s disease with GBA mutations
THOUSAND OAKS, Calif., September 4, 2024 – Capsida Biotherapeutics (“Capsida”), a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, today announced that the company will participate in the following investor and industry conferences in September and October.
Management will highlight the progress with Capsida’s wholly owned IV-administered programs – CAP-002 in genetic epilepsy due to STXBP1 mutations and CAP-003 in Parkinson’s disease associated with GBA mutations. Both programs are on track to enter the clinic in the first half of 2025.
Morgan Stanley Healthcare Conference (September 4-6, 2024)
Format: Corporate Presentation
Date: Thursday, September 5, 2024
Time: 4:05 PM ET
Location: New York, NY
Mass General Brigham World Medical Innovation Forum in Partnership with Bank of America (September 23-25, 2024)
Format: Panel: ‘The Innovation Gap: A Review of the Future of Viral Vector Manufacturing and the Delivery of Genetic Medicines’
Date: Monday, September 23, 2024
Time: 4:05 PM ET
Location: Boston, MA
Bank of America Healthcare Trailblazers Private Company Conference (September 25, 2024)
Format: One-on-one investor meetings
Date: Wednesday, September 25, 2024
Location: Boston, MA
Chardan’s 8th Annual Genetic Medicines Conference (September 30-October 1, 2024)
Format:
Panel: ‘Engineering of AAVs: The Promise of Next Gen AAVs’
Corporate Presentation
One-on-one investor meetings
Date: Monday, September 30, 2024
Time:
Panel: 9:30 AM ET
Corporate Presentation: 4:00 PM ET
Location: New York, NY
Cell & Gene Meeting on the Mesa (October 7-9, 2024)
Format: Corporate Presentation
Date: Tuesday, October 8, 2024
Time: 3:45 PM MT
Location: Phoenix, AZ
The Capsida corporate presentation can be accessed by visiting the News section of the Company’s website at www.capsida.com.
About Capsida Biotherapeutics
Capsida Biotherapeutics is a fully integrated gene therapy company with a central nervous system (CNS) pipeline consisting of disease modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida’s intravenously (IV) administered gene therapies utilize proprietary engineered capsids that enable high transduction levels to desired tissues and cells, while limiting tropism to non-target organs, such as the liver. Capsida has three wholly owned programs, including potential best-in-class treatments for genetic epilepsy due to STXBP1 mutations and Parkinson’s disease associated with GBA mutations, both of which are in IND-enabling studies and on track to enter the clinic in the first half of 2025. In addition to its wholly owned programs, the Company has validating CNS partnerships with AbbVie, Lilly, CRISPR Therapeutics, and the AbbVie partnership was expanded to include ophthalmology disorders. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at www.capsida.com.
Media Contact:
Greig Communications, Inc.
Kathy Vincent
kathy@greigcommunications.com